Effects of the Interaction of Variants of the Serotonin Transporter and Brain-Derived Neurotrophic Factor on Platelet Serotonin Levels in Stroke Patients

Golimbet, V. E.; Os, Brusov; Фактор, М. И.; Zlobina, G. P.; Лежейко, Т. В.; Lavrushina, O. M.; Petrova, Elizaveta A.; Savina, Maria A.; Skvortsova, Veronika

doi:10.1007/s11055-011-9454-1

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance to some early reports indicating decreased plasma serotonin levels in patients with acute ischemic stroke [29]. On the other hand, some studies reported elevated post-stroke plasma serotonin levels compared to healthy subjects [30] while some reported no significant differences in serotonin levels [31]. The suggested reason could be in the dynamics of the platelet serotonin (PS) content in one-day period after stroke, since the patients with low PS content had more severe status than patients with values greater than normal [31].…”

Section: Discussionsupporting

confidence: 92%

“…On the other hand, some studies reported elevated post-stroke plasma serotonin levels compared to healthy subjects [30] while some reported no significant differences in serotonin levels [31]. The suggested reason could be in the dynamics of the platelet serotonin (PS) content in one-day period after stroke, since the patients with low PS content had more severe status than patients with values greater than normal [31]. Serotonin is well known as excitatory glutamatergic neurotransmitter that modulates neural activity and regulates mood and behaviour, but it also very important regulator of platelet aggregation and cardiovascular function [32].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Preprint

View full text Add to dashboard Cite

Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Identifying reliable biomarkers for early detection, prognostics and therapy is a criti-cal imperative for improving the stroke patient treatment. Metabolomics has been shown as a promising tool for biomarker discovery since many of the post-ischemic metabolites can found in the plasma or serum of the patient. In this research, we have performed comparative targeted metabolomic analysis of stroke thrombi, patient serums and healthy control serums in order to determine the alteration in the patients’ metabolome. The most statistically altered metabolites characterized in patient compared to control serums were glutamate and serotonin, followed by several lipid metabolites (phospholipids and triacylglycerols) and glucose. In stroke thrombi compared to patient’s serums, the most significantly altered metabolites were classified as li-pids, with choline-containing phospholipids and sphingomyelins having the highest discrimi-natory score. The results of this study could help in understanding the roles of different meta-bolic changes occurring during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers of the ischemic stroke.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 98%

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The number of platelet serotonin transporters was low shortly after stroke compared with normal subjects, but no difference was found between stroke patients who developed PSD and those who did not. Therefore, a low number of platelet serotonin transporters may be a non-specific state marker for acute stroke and is not directly related with PSD [24,25] .…”

Section: Managing Psdmentioning

confidence: 99%

Management of Poststroke Neuropsychiatric Disorders

Khan

Chen

Zhang

et al. 2016

Translational Neuroscience and Clinics

View full text Add to dashboard Cite

Post-stroke neuropsychiatric (NP) disorders are common and have complex etiologies. Multiple factors such as lesion location, personality characteristics, socioeconomic status, pre-stroke psychiatric history, and family support are the determining factors in most cases. Although depression and anxiety are more common, emotional incontinence and catastrophic reactions are also frequently observed. Post-stroke depression (PSD) has been associated with an increased risk of stroke recurrence. Despite its serious consequences and high prevalence, PSD remains undetected and untreated. Treatment options of NP disorders depend on severity, presentation at the time of diagnosis, and patient cooperation, and include antidepressants, mood stabilizers, exercise therapy, psychotherapy, and even revascularization. The efficient management of NP disorders improves outcomes, quality of life, and survival rates in poststroke patients. However, very few studies have identified definitive treatment for these patients; therefore, further research is required.

show abstract

Comparative Targeted Metabolomics of Ischemic Stroke: Thrombi and Serum Profiling for the Identification of Stroke-Related Metabolites

Karmelić,

Rubić,

Starčević

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Ischemic stroke is one of the leading causes of death and permanent disability in the world. Rapid diagnosis and intervention are crucial for reducing its consequences on individuals and societies. Therefore, identifying reliable biomarkers for early detection, prognostics, and therapy can facilitate the early prediction and prevention of stroke. Metabolomics has been shown as a promising tool for biomarker discovery since many post-ischemic metabolites can be found in the plasma or serum of the patient. In this research, we performed a comparative targeted metabolomic analysis of stroke thrombi, stroke patient serums, and healthy control serums in order to determine the alteration in the patients’ metabolomes, which might serve as biomarkers for early prediction or stroke prevention. The most statistically altered metabolites characterized in the patient serums compared with the control serums were glutamate and serotonin, followed by phospholipids and triacylglycerols. In stroke thrombi compared with the patients’ serums, the most significantly altered metabolites were classified as lipids, with choline-containing phospholipids and sphingomyelins having the highest discriminatory score. The results of this preliminary study could help in understanding the roles of different metabolic changes that occur during thrombosis and cerebral ischemia and possibly suggest new metabolic biomarkers for ischemic stroke.

show abstract

Effects of the Interaction of Variants of the Serotonin Transporter and Brain-Derived Neurotrophic Factor on Platelet Serotonin Levels in Stroke Patients

Cited by 3 publications

References 9 publications

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Comparative Targeted Metabolomics in Ischemic Stroke Patients: Profiling Thrombi and Serums Samples for Identification of Stroke-related Metabolites

Management of Poststroke Neuropsychiatric Disorders

Comparative Targeted Metabolomics of Ischemic Stroke: Thrombi and Serum Profiling for the Identification of Stroke-Related Metabolites

Contact Info

Product

Resources

About